For Alzheimer S Scientists The Amyloid Debate Has No Easy Answers
But the FDA determined that amyloid clearance was enough, and it gave Aduhelm accelerated approval. The decision was wildly controversial—it prompted internal and congressional investigations, and three members of the advisory committee resigned. Suddenly, journalists across the country were scrambling to break down the “amyloid hypothesis” for their readers, in order to explain why the FDA would approve a drug without evidence that it reduced symptoms—and why that decision provoked so much debate....